| Symbol | MBRX |
|---|---|
| Name | MOLECULIN BIOTECH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5300 MEMORIAL DRIVE,SUITE 950, HOUSTON, Texas, 77007, United States |
| Telephone | +1 713 300-5160 |
| Fax | — |
| — | |
| Website | https://www.moleculin.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001659617 |
| Description | Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. Additional info from NASDAQ: |
2026-08-14 18:06
New Form PRE 14A - Moleculin Biotech, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001437749-26-028049 <b>Size:</b> 1 MB
Read more
2026-08-14 12:30
(30% Negative) MOLECULIN BIOTECH, INC. (MBRX) Reports Q3 2026 Financial Results
Read more
2026-08-14 12:30
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Read more
2026-08-10 19:38
New Form SCHEDULE 13G - Moleculin Biotech, Inc. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001649553-26-000082 <b>Size:</b> 15 KB
Read more
2026-08-03 21:11
(99% Neutral) MOLECULIN BIOTECH, INC. (MBRX) Announces Business Combination
Read more
2026-07-31 12:10
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Read more
2026-07-31 12:00
(90% Positive) MOLECULIN BIOTECH, INC. (MBRX) Announces Clinical Development Update
Read more
2026-07-30 18:10
New Form S-1/A - Moleculin Biotech, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001437749-26-025100 <b>Size:</b> 426 KB
Read more
2026-07-29 10:41
New Form S-1 - Moleculin Biotech, Inc. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001437749-26-024774 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Li… | Phase2 | Acute Myeloid Leukaemia (AML) | Recruiting | 2025-03-12 | 2030-08-01 | ClinicalTrials.gov |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblas… | Phase2 | Glioblastoma, IDH-Wildtype | Recruiting | 2024-05-22 | 2028-12-27 | ClinicalTrials.gov |
| NCT05319587 | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment o… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2022-09-29 | 2023-08-10 | ClinicalTrials.gov |
| NCT05195723 | Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2022-05-11 | 2022-10-24 | ClinicalTrials.gov |
| NCT04887298 | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sar… | Phase1 | Sarcoma,Soft Tissue | Completed | 2021-06-05 | 2024-08-06 | ClinicalTrials.gov |
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymph… | Phase1 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Completed | 2019-03-08 | 2020-11-15 | ClinicalTrials.gov |
| NCT03388749 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid L… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2018-12-17 | 2022-02-14 | ClinicalTrials.gov |
| NCT03315039 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid L… | Phase1 | Leukemia, Myeloid, Acute | Completed | 2018-03-28 | 2020-06-20 | ClinicalTrials.gov |
| NCT01826201 | Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis | Phase2 | Psoriasis | Completed | 2013-03-01 | 2013-08-01 | ClinicalTrials.gov |
Total clinical trials: 9
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Surgical Procedure | Procedure | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| STAT3 Inhibitor WP1066 | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Radiation Therapy | Drug | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Biospecimen Collection | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01826201 |
| MOL4239 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT01826201 |
| WP1220 | Other | Phase PHASE1 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | COMPLETED | NCT04702503 |
| Liposomal Annamycin | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT03315039 |
| Liposomal Annamycin | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT03388749 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195723 |
| WP1122 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195723 |
| Liposomal Annamycin (L-Annamycin) | Other | Phase PHASE1 | Sarcoma,Soft Tissue | COMPLETED | NCT04887298 |
| Cytarabine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT05319587 |
| Liposomal Annamycin | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT05319587 |
| Surgical Procedure | Procedure | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| STAT3 Inhibitor WP1066 | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Radiation Therapy | Drug | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Biospecimen Collection | Other | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | Other | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection. | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Placebo in combination with Cytarabine Injection | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia (AML) | RECRUITING | NCT06788756 |
| Surgical Procedure | PROCEDURE | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| STAT3 Inhibitor WP1066 | DRUG | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Radiation Therapy | RADIATION | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Glioblastoma, IDH-Wildtype | RECRUITING | NCT05879250 |
| Cytarabine | DRUG | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT05319587 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195723 |
| WP1122 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195723 |
| Liposomal Annamycin (L-Annamycin) | DRUG | Phase PHASE1 | Sarcoma,Soft Tissue | COMPLETED | NCT04887298 |
| WP1220 | DRUG | Phase PHASE1 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | COMPLETED | NCT04702503 |
| Liposomal Annamycin | DRUG | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT05319587 |
Total products: 79